drug
LTG-001
Phase 2updated 3mo agoby Latigo Biotherapeutics Inc
Phase 2community read0 votes
🐶 often sniffed alongside
top 3all catalysts(1)
Trials studying LTG-001
- phase1A Phase 1 Single and Multiple Ascending Dose Study of LTG-001 Administered Orally in Healthy Participants
- phase2An Efficacy and Safety Study of LTG-001 Following Abdominoplasty
- phase1A Study Comparing LTG-001 SDD Formulation To LTG-001 Crystalline Immediate Release Tablets In Healthy Participants
- phase2This is a Study Evaluating the Efficacy and Safety of LTG-001 for Acute Pain After Surgical Removal of Impacted Third Molars
News(5)
- BlossomHill, Latigo bloom on Nasdaq with oversubscribed IPOsBlossomHill Therapeutics will use its $150 million IPO proceeds to power the Phase 1/2 development of a non-small cell lung cancer drug, while Latigo Therapeutics will bring in more than $345 milli…biospace · 10d ago
- BlossomHill, Latigo outshine IPO expectations with oversubscribed debutsTwo growing biotechs blasted through their IPO expectations Friday, with Blossom Hill Therapeutics and Latigo Biotherapeutics each raising at least 30% more than expected in their stock market debuts.fiercebiotech · 13d ago
- Latigo laces up for $247M IPO to fund non-opioid pain drug rival to Vertex’s JournavxLatigo Biotherapeutics has fleshed out its plans for an IPO to finance the development of its clinical-stage pipeline of non-opioid pain management drugs.fiercebiotech · 16d ago
- STAT+: Latigo reports mid-stage success for would-be rival to Vertex’s pain drug JournavxLatigo Biotherapeutics published positive data for an acute-pain drug meant to rival a Vertex medicine already on the marketstat · 22d ago
- Latigo preps IPO to fund non-opioid pain drug rival to Vertex’s JournaxLatigo Biotherapeutics is preparing to go public in order to bankroll the development of its clinical-stage pipeline of non-opioid pain management drugs.fiercebiotech · 1mo ago
Data sources
last refreshed 38m ago
Found something off?
comments(0)
5-min edit window · permanent after that